Cargando…

Comparison of Cefepime with Piperacillin/Tazobactam Treatment in Patients with Hospital-Acquired Pneumonia

Although cefepime and piperacillin/tazobactam are commonly prescribed for the treatment of hospital-acquired pneumonia (HAP), which one is the superior therapy remains unclear. Using Korean National Health Insurance Service data from January 2018 to December 2018, we compared the clinical outcomes o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Bo-Guen, Kang, Danbee, Min, Kyung Hoon, Cho, Juhee, Jeon, Kyeongman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295393/ https://www.ncbi.nlm.nih.gov/pubmed/37370303 http://dx.doi.org/10.3390/antibiotics12060984

Ejemplares similares

Comprehensive risk assessment for hospital-acquired pneumonia: sociodemographic, clinical, and hospital environmental factors associated with the incidence of hospital-acquired pneumonia
por: Kim, Bo-Guen, et al.
Publicado: (2022)

A Comparison Between Cefepime and Piperacillin-Tazobactam in the Management of Septic Shock
por: Ross, Robert C, et al.
Publicado: (2021)

726. Risk factor analysis for cefepime and piperacillin/tazobactam resistant organisms
por: Pham, Tho H, et al.
Publicado: (2023)

212. Effectiveness of Empirical Piperacillin/tazobactam Compared to Cefepime for Bloodstream Infection Caused by Gram-Negative Bacilli
por: Ho Lee, Young, et al.
Publicado: (2023)

212. Acute Kidney Injury with Piperacillin-tazobactam versus Cefepime in Combination with Vancomycin
por: Nguyen, Phuong Khanh, et al.
Publicado: (2020)

80. Pharmacoeconomic Analysis Comparing the Empiric Utilization of Cefepime Versus Piperacillin/tazobactam
por: Olmack, Kelsey, et al.
Publicado: (2020)

2576. Piperacillin-Tazobactam or Cefepime for Treatment of Third Generation Cephalosporin Resistant Pneumonia in Intensive Care Unit Patients
por: DeLaurentis, Clare, et al.
Publicado: (2023)

2687. Extended Infusions of Piperacillin/Tazobactam vs. Cefepime for Empiric Treatment of Neutropenic Fever
por: Norman, Sarah, et al.
Publicado: (2019)

1306. Comparison of the Use of Extended and Intermittent Infusion Cefepime and Piperacillin/tazobactam in Non-critically Ill, Obese Patients
por: Marg, Carolyn, et al.
Publicado: (2020)

2436. Use of Piperacillin/Tazobactam vs. Cefepime or Carbapenem for Infections Due to Serratia, Citrobacter, or Enterobacter
por: Go, James, et al.
Publicado: (2018)

Mechanisms of Piperacillin/Tazobactam Nephrotoxicity: Piperacillin/Tazobactam-Induced Direct Tubular Damage in Mice
por: Yang, Jihyun, et al.
Publicado: (2023)

2893 B. Effect of Cefepime versus Piperacillin-Tazobactam in Adults Hospitalized with Acute Infection: A Randomized Clinical Trial
por: Qian, Edward, et al.
Publicado: (2023)

Piperacillin/tazobactam: Eosinophilic-pneumonia: case report
Publicado: (2021)

Clinical Efficacy of Cefoperazone-Sulbactam versus Piperacillin-Tazobactam in the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia
por: Chen, Chia-Hung, et al.
Publicado: (2021)

2385. Evaluating the Antibiotic Risk for Clostridioides difficile Infection (CDI): Comparing Piperacillin/Tazobactam to Cefepime and Ceftazidime
por: Rathod, Shardul, et al.
Publicado: (2019)

Progression of kidney injury with the combination of vancomycin and piperacillin-tazobactam or cefepime in sepsis-associated acute kidney injury
por: Whitenack, Kaylee, et al.
Publicado: (2022)

BIChromET: A Chromogenic Culture Medium for Detection of Piperacillin/Tazobactam and Cefepime Resistance in Pseudomonas aeruginosa
por: Ortiz de la Rosa, José Manuel, et al.
Publicado: (2023)

Piperacillin/Tazobactam (ZOSYN)
por: Culver, Stephanie M., et al.
Publicado: (1996)

Piperacillin/tazobactam: Acute eosinophilic pneumonia: case report
Publicado: (2021)

The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia
por: Lai, Chih-Cheng, et al.
Publicado: (2023)

Incidence of Acute Kidney Injury Among Intensive Care Unit Patients Receiving Vancomycin in Combination with Cefepime or Piperacillin–Tazobactam
por: Rutter, W Cliff, et al.
Publicado: (2017)

50. Comparative Incidence of Acute Kidney Injury in Septic Patients Treated with Vancomycin in Combination with Piperacillin/Tazobactam vs. Cefepime
por: Deja, Erin, et al.
Publicado: (2020)

Piperacillin/tazobactam Induced Myelosuppression
por: Lee, Kirsty Wai Chung, et al.
Publicado: (2009)

Re-evaluation of cefepime or piperacillin/tazobactam to decrease use of carbapenems in ESBL-producing Enterobacterales urinary tract infections (REDUCE-UTI)
por: Branton, Alexander C, et al.
Publicado: (2023)

Selection of piperacillin/tazobactam infusion mode guided by SOFA score in cancer patients with hospital-acquired pneumonia: a randomized controlled study
por: Lyu, Yang, et al.
Publicado: (2017)

Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial
por: Bao, H., et al.
Publicado: (2016)

Clinical Benefits of Piperacillin/Tazobactam versus a Combination of Ceftriaxone and Clindamycin in the Treatment of Early, Non-Ventilator, Hospital-Acquired Pneumonia in a Community-Based Hospital
por: Park, Ga Eun, et al.
Publicado: (2020)

DRESS syndrome induced by piperacillin-tazobactam
por: Sanchez-Gonzalez, Maria-Jose, et al.
Publicado: (2014)

Piperacillin/tazobactam administered by continuous or intermittent infusion for the treatment of nosocomial pneumonia
por: Lorente, L, et al.
Publicado: (2009)

Rapid Detection of Piperacillin-Tazobactam Resistance in Klebsiella pneumoniae and Escherichia coli
por: Ortiz de la Rosa, José Manuel, et al.
Publicado: (2023)

1576. Re-Evaluation of cefepime or piperacillin-tazobactam to Decrease Use of Carbapenems in ESBL-Producing Enterobacterales BloodStream Infections (REDUCE-BSI)
por: Vu, Catherine H, et al.
Publicado: (2020)

1257. Re-Evaluation of Cefepime or Piperacillin-Tazobactam to Decrease Use of Carbapenems in ESBL-Producing Enterobacterales Urinary Tract Infections (REDUCE-UTI)
por: Branton, Alexander C, et al.
Publicado: (2021)

Is Piperacillin-Tazobactam an Appropriate Empirical Agent for Hospital-Acquired Sepsis and Community-Acquired Septic Shock of Unknown Origin in Australia?
por: Gage-Brown, Alice, et al.
Publicado: (2022)

Comparison of Antimicrobial Sensitivity to Older and Newer Quinolones versus Piperacillin-Tazobactam, Cefepime and Meropenem in Febrile Patients with Cancer in two Referral Pediatric Centers in Tehran, Iran
por: Nateghian, AR., et al.
Publicado: (2014)

2221. Comparison of Vancomycin with Either Piperacillin/Tazobactam or Cefepime for the Incidence of Acute Kidney Injury in a Patient Population with a High Prevalence of Preexisting Kidney Dysfunction
por: Moran, Ryan, et al.
Publicado: (2023)

Pharmacokinetic/pharmacodynamic predictions and clinical outcomes of patients with augmented renal clearance and Pseudomonas aeruginosa bacteremia and/or pneumonia treated with extended infusion cefepime versus extended infusion piperacillin/tazobactam
por: Gerlach, Anthony T., et al.
Publicado: (2019)

Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase–producing Enterobacterales bloodstream infections (REDUCE-BSI)
por: Vu, Catherine H., et al.
Publicado: (2022)

400. Comparison of Tolerance and Microbiological Efficacy of Cefepime and Piperacillin/Tazobactam in Combination with Vancomycin as Empirical Antimicrobial Therapy of Prosthetic Joint Infection: A Propensity-Matched Cohort Study
por: Triffault-Fillit, Claire, et al.
Publicado: (2019)

Enterobacter endophthalmitis: Treatment with intravitreal tazobactam- piperacillin
por: Singh, Trehan Hemant, et al.
Publicado: (2007)

Piperacillin-tazobactam-induced hypokalemia and metabolic alkalosis
por: Zaki, Syed Ahmed, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_gh1h3u14b2otmici9sc8es3875